SCHEMBL8771632

SCHEMBL8771632

CCCCCC1CCC(c2ccc(-c3ccc(C(=O)Nc4ccc(C)c(C(F)(F)F)c4)cc3)cc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
MAPK14 Q16539 8/20 0.44
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HDAC3 O15379 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
DGAT1 O75907 1/20 0.42
LDLR P01130 1/20 0.41
CYP2C9 P11712 1/20 0.41
MCHR1 Q99705 2/20 0.41
RAF1 P04049 1/20 0.41
HSPB1 P04792 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21117275 0.97 MAPT (0.49) MAPTALDH1A1LMNAMAPK14MEN1
SCHEMBL12125151 0.89 ALDH1A1 (0.51) MAPTALDH1A1LMNAMAPK14NPC1
SCHEMBL12125154 0.87 ALDH1A1 (0.50) MAPTALDH1A1LMNAMAPK14NPC1
SCHEMBL12125152 0.86 ALDH1A1 (0.54) MAPTALDH1A1LMNAMAPK14MEN1
SCHEMBL12125158 0.85 ALDH1A1 (0.53) MAPTALDH1A1LMNAMAPK14NPC1
SCHEMBL8771797 0.84 MAPT (0.54) MAPTALDH1A1LMNAMAPK14NPC1
SCHEMBL8771609 0.84 MAPT (0.54) MAPTALDH1A1LMNAMAPK14NPC1
SCHEMBL16775458 0.84 MAPT (0.54) MAPTALDH1A1LMNAMAPK14NPC1
SCHEMBL1333625 0.83 ALDH1A1 (0.47) MAPTALDH1A1LMNAHDAC3HDAC11
SCHEMBL1333623 0.83 ALDH1A1 (0.47) MAPTALDH1A1LMNAHDAC3HDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9309455-B2 Indeno-fused ring compounds TRANSITIONS OPTICAL, INC. (US) 2016-04-12 US disclosed
US-9309455-B2 Indeno-fused ring compounds TRANSITIONS OPTICAL, INC. (US) 2016-04-12 US disclosed
US-20140166948-A1 INDENO-FUSED RING COMPOUNDS TRANSITIONS OPTICAL LIMITED (IE) 2014-06-19 US disclosed
US-20140166948-A1 INDENO-FUSED RING COMPOUNDS TRANSITIONS OPTICAL LIMITED (IE) 2014-06-19 US disclosed
US-20120126185-A1 INDENO-FUSED RING COMPOUNDS TRANSITIONS OPTICAL, INC. (US) 2012-05-24 US disclosed
US-20120126185-A1 INDENO-FUSED RING COMPOUNDS TRANSITIONS OPTICAL, INC. (US) 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120126185-A1 INDENO-FUSED RING COMPOUNDS CRY2, SQOR, INTS6 MAPT 2624/4885ALDH1A1 498/4885LMNA 1680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.